1. Scrip
  2. >>Business

Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors

 
• By Sukaina Virji

Next generation DNA repair is the basis of new oncology-focused Artios Pharma, which has launched with a £25m series A round and a ‘PARP-esque’ discovery program.

Artios Pharma Ltd., a new company focused on developing novel cancer treatments targeting DNA damage response, has been launched with a £25 million series A financing led by SV Life Sciences.

DNA damage response is a mechanism through which cells repair damaged DNA. However, research suggests tumors manipulate this ability, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.